Two easy ways to obtain
SINUVA for your patients

1. Buy & Bill

You can buy SINUVA directly via a Specialty Distributor and treat patients in your office or clinic. When purchasing SINUVA directly from a distributor, providers are responsible for obtaining authorization and submitting claims directly to the payor. For additional information on how to bill for SINUVA, see the Billing and Coding information below.

To order SINUVA, please contact a Specialty Distributor listed below.

For Physician Offices

1-800-543-2111

For Facilities Offices

1-800-746-6273

The ASCENT Reimbursement Support Program can assist with the buy-and-bill process by researching and verifying patient insurance benefits for SINUVA. To utilize this service, complete the Patient Enrollment Form that can be downloaded below and fax it to 1-844-745-2358.

For questions, call ASCENT directly at 1-833-4-SINUVA (1-833-474-6882)

2. Specialty Pharmacy

A limited network of Specialty Pharmacies can fill a prescription for SINUVA and ship product directly to the provider’s office or clinic for administration. Use of this option is dependent upon a patient’s insurance coverage. Specialty Pharmacies may be able to conduct product pre-authorization requirements and bill the insurance company directly for SINUVA. When this occurs, providers should only bill payors for the services related to insertion of SINUVA.

To obtain SINUVA for patients using a Specialty Pharmacy, complete the required Specialty Pharmacy Enrollment Form and submit directly to the Specialty Pharmacy of choice.

1-866-575-8780

1-833-858-7788

Disclaimer: Intersect ENT does not recommend the use of any particular specialty distributor or specialty pharmacy. This information is provided for reference purposes only and all decisions are at the discretion of the physician and their practice.

Billing and Coding for SINUVA

This information is provided to assist you with submission of claims to payors. Check each payor’s specific guidelines for coding and billing.

Listed below are the ICD-10 codes for Nasal Polyps.

ICD-10 CodeDescriptor
J33.0Polyp of nasal cavity
J33.1Polypoid sinus degeneration
J33.8Other polyp or sinus
J33.9Nasal polyp, unspecified

HCPCS CodesDescriptor
J3490Unclassified Drugs

NDC NumberDescriptor
10599-0003-01SINUVA (mometasone furoate) Sinus Implant

For additional SINUVA reimbursement support, please contact reimbursement@intersectent.com

Stay Up-to-Date on SINUVA

Sign up below for the latest information about the SINUVA Sinus Implant.

INDICATION

SINUVA™ Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.

IMPORTANT SAFETY INFORMATION

Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids. If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

SINUVA is made from bioabsorbable polymers designed to soften over time. As the implant softens and polyps decrease, the implant may be expelled out of the nose on its own or with actions such as sneezing or forceful nose blowing. The implant can be removed 90 days after placement or earlier at the physician’s discretion. Repeat administration of SINUVA has not been studied.

As with other endoscopic sinus procedures, there are risks associated with the insertion or removal of SINUVA. SINUVA should be inserted by physicians trained in otolaryngology.

The nasal mucosa adjacent to the SINUVA Sinus Implant should be monitored for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid the use of SINUVA in patients with nasal ulcers or trauma.

The most common adverse reactions observed in clinical studies were bronchitis, nasopharyngitis, otitis media, headache, presyncope, asthma, and epistaxis.

Patients experiencing excessive nasal bleeding, symptoms of infection or symptoms suggesting that the implant has moved, such as irritation or a choking sensation in the back of the throat, should immediately contact a healthcare professional.

Close monitoring is recommended if patients have a change of vision or a history of increased intraocular pressure, glaucoma and/or cataracts.

You may report side effects to your physician or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . You may also report side effects to Intersect ENT at 1-866-531-6004.

RX Only. For important risk and use information about SINUVA, please see Full Prescribing Information.

Reference: SINUVA Prescribing Information, Intersect ENT. December 2017.

IMPORTANT SAFETY INFORMATION

Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids. If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal. Continue Reading

IMPORTANT SAFETY INFORMATION

Patients with a known hypersensitivity to the mometasone furoate drug or any of the ingredients in SINUVA, should not use SINUVA. Continue Reading

Start typing and press Enter to search